

[EBMT](#)

[Annual report](#)

[2023](#)



[Science Education Patient Care & Advocacy](#)

[Our Society](#) [Our Mission, Vision & Values](#) [EBMT Membership 2023](#) [Organisational Structure 2023](#) [Financial Highlights 2023](#) [EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Emanuele Angelucci

HWP Chair

Italy

Major achievements

The elections for the HWP took place in April 2023 and the election of the Chair was announced during the General Assembly at the 49th Annual Meeting of the EBMT on 25 April.

During the rest of the year to set up the WP and start activities the following actions were carried out:

1. Josu de la Fuente was chosen as the WP Secretary
2. Constitution of the Scientific Board
3. Migration of the six studies already approved by the Paediatric WP. It should be noted that these studies were not discussed by this working group. One of these studies is very difficult to be completed because of the complexity of the questions (see below). Migration issues have been agreed with the PWP chair.
4. On-site meeting with the statistics office in Paris. During this meeting it was noted that the compilation of the questionnaire was very limited due to the complexity and number of questions. A new shortened questionnaire was developed and discussed with the PI. A seventh study has been proposed and will be discussed at the next HWP Meeting.
5. Agreement with EHA for development of EHA/EBMT guidelines for gene therapy in Sickle cell disease
6. The first HWP Meeting took place in Jan 2024.

Principal research studies

[Outcomes after graft failure of allogeneic hematopoietic stem cell transplantation in patients with SCD](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Other non-malignant disorders](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Haemoglobinopathies Working Party \(HWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Josu de la Fuente](#)

[Impact of ABO Incompatibility on HSCT outcome in hemoglobinopathies: A](#)

[Retrospective Registry Study from the Paediatric Diseases Working Party \(PDWP\) of the European Society for Blood and Marrow Transplantation \(EBMT\)](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Other non-malignant disorders](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Haemoglobinopathies Working Party \(HWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Katharina Kleinschmidt](#)

[Trend and outcome of HSCT in Thalassemia inside the EBMT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Other non-malignant disorders](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Haemoglobinopathies Working Party \(HWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Baroncini Donatella](#)

[Allogenic Hematopoietic Stem Cell Transplantation for Adult Sickle Cell Disease: A registry study on behalf of the EBMT Pediatric Disease Working Party](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Other non-malignant disorders](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Haemoglobinopathies Working Party \(HWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Can Boga](#)

[Treo Flu vs Bu Flu +/-Thio in SCD from 2010-2014 \(extended to 2017\), part of first](#)

[Medac Study](#)

[Study type](#)

[Retrospective Studies](#)

Diseases

-
Group

Paediatric Diseases Working Party (PDWP)

Type of treatment

-
Principal investigator

Cseh Annamaria

Mixed chimerism after related CB HSCT with hemoglobinopathies

Study type

Retrospective Studies

Diseases

Other non-malignant disorders

Group

Paediatric Diseases Working Party (PDWP)


Haemoglobinopathies Working Party (HWP)

Type of treatment

Allogeneic

Principal investigator

Vanderson Rocha (Brazil)



2019 2020 2021 2022

Oral presentations	2	1	2	6
Poster presentations	4	3	2	5
Educational events	2	0	1	1

[VISIT THE HWP WEBPAGE](#)